CANBERA (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) and Telix Pharmaceuticals Ltd. (TLX, TLX.AX) announced Monday a collaboration to jointly develop and commercialize next generation radiopharmaceutical therapies.
The collaboration combines Regeneron's extensive biologics expertise, including bispecific antibody discovery, with Telix's radiopharmaceutical development platform, global manufacturing capabilities and supply chain infrastructure. It willinclude multiple solid tumor targets from Regeneron's portfolio of antibodies, generated from VelocImmune mice.
With a shared commitment to precision oncology, the two companies also plan to develop radio-diagnostics to support patient selection and treatment response assessment.
Under the terms of the agreement, Telix will receive an upfront cash payment of $40 million from Regeneron for access to its radiopharmaceutical manufacturing platform for four initial therapeutic programs, with Regeneron having the option to expand to include four additional programs with additional upfront payments.
Telix and Regeneron will share equally in the global commercialization costs and potential profits, with Telix retaining the option to co-promote certain potential products.
Should Telix opt-out of the co-funding model for a particular program, it is instead eligible to receive up to $535 million in development and commercial milestones, plus low double-digit royalites on future net sales, for that program.
Telix and Regeneron will also jointly develop diagnostic assets, with Telix leading commercialization and Regeneron receiving a set percentage of profits.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
